Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
295 GBX | 0.00% | -8.67% | -16.31% |
Apr. 02 | MaxCyte inks deal with Be Bio; Orcadian firms farmout | AN |
Apr. 02 | MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.42% | 387M | |
+7.99% | 220B | |
+6.31% | 183B | |
+9.77% | 133B | |
+24.46% | 107B | |
-0.91% | 63.05B | |
+11.93% | 51.74B | |
+4.81% | 50.47B | |
-0.21% | 40.91B | |
+23.67% | 31.91B |
- Stock Market
- Equities
- MXCT Stock
- News MaxCyte, Inc.
- MaxCyte Inks Platform License Deal With Cancer Medicine Developer Imugene